Literature DB >> 25340145

Significance of segmental glomerulosclerosis in IgA nephropathy: What is the evidence?

Muhammed Mubarak1, Hamid Nasri2.   

Abstract

Entities:  

Keywords:  Columbia classification; Focal segmental glomerulosclerosis; IgA nephropathy; Oxford classification; Proteinuria; Renal failure

Year:  2013        PMID: 25340145      PMCID: PMC4206031          DOI: 10.12861/jrip.2013.36

Source DB:  PubMed          Journal:  J Renal Inj Prev        ISSN: 2345-2781


× No keyword cloud information.

Implication for health policy/practice/research/medical education:

Primary IgA nephropathy (IgAN) is the commonest glomerulopathy worldwide. Its clinical presentation, histology and prognosis vary widely. The lesions of segmental glomerulosclerosis are common in IgAN and represent participation of at least three pathogenetic mechanisms. It is important to identify the different subtypes of segmental sclerosing lesions as these are of prognostic value. Primary IgA nephropathy (IgAN) is the commonest primary glomerular disease worldwide (1,2). The disease is notorious for a wide variation in the epidemiology, clinical presentation, histology, and the prognosis (3,4). The only unifying feature is the presence of dominant or co-dominant IgA deposits in the mesangium and occasionally in the peripheral capillary loops on immunofluorescence (IF) microscopy (5-9). The reported frequency ranges from 2 to 52% of all renal diseases in renal biopsy series from different parts of the world (1,2). The clinical presentation ranges from asymptomatic to acute renal failure to end-stage renal disease (ESRD). The typical pathological lesion is the mesangial proliferative glomerulonephritis (MesPGN), but the spectrum of pathological lesions is broad and the morphological lesions of segmental glomerulosclerosis are common on renal biopsies in patients with primary IgAN (10-16). Hill et al. noted in their preliminary analysis the presence of such lesions in 66% of cases (17). In a subsequent detailed study, some form of segmental glomerulosclerosis was found in 78.9% of biopsies (18,19). The original study cohort of the Oxford classification showed such lesions in 76% of the biopsies (10). We also found the lesions of segmental glomerulosclerosis in 63.2% in a cohort of consecutive cases of primary IgAN (unpublished data). The exact origin and pathogenesis of these lesions is still enigmatic. It is possible that, there are at least three ways by which segmental glomerulosclerosis may occur in patients with IgAN. First; by post-inflammatory scarring of segmental proliferative or necrotizing lesions, commonly observed in this disease, second; due to compensatory hemodynamic changes following nephron loss, and finally by primary podocyte damage, perhaps due to mediators released from mesangial cells (18,19) or perhaps due to direct cytotoxic action of IgA1 deposits. This schema of events is shown schematically in Figure 1.
Figure 1
Schematic diagram showing the different possible pathways of origin of segmental glomerulosclerosis in IgA nephropathy (IgAN) We and some other investigators are of the view that it is possible to identify two types of segmental sclerosing lesions on renal biopsy examination in these patients (17,18). First is the focal segmental glomerulosclerosis (FSGS), which is classified as a separate category in the Hass classification of IgAN and more recently defined more elaborately in Columbia classification (20,21). This lesion may be considered as “definite FSGS” lesion or the FSGS of Columbia classification and is the result of podocyte injury. How the podocyte injury is induced by IgA deposits is not known at preset. The second mechanism involves fibrosis or healing process arising on the background of segmental proliferative and necrotizing lesions. This may be considered the “indeterminate form” of segmental glomerulosclerosis or FSGS of Oxford classification. The prognosis of these types of segmental lesions is different as observed by Hill et al. who noted that patients with frank FSGS had a prognosis, with 50% ending on dialysis, compared with 4.1% of those without such lesions. Patients with indeterminate segmental lesions had a prognosis intermediate between the other two groups, with 36.1% ending on dialysis (17). However, this issue is still far from completely settled (22-24). Regarding the pathological features distinguishing between these two types of segmental lesions, Hill et al. suggested that intracapillary hyalinosis and prominent podocyte hypertrophy/hyperplasia favor the diagnosis of definite FSGS over indeterminate segmental glomerulosclerosis (17,18). The pathological criteria for the diagnosis of Oxford segmental lesion are less stringent and require the mere presence of segmental increase in mesangial matrix with obliteration of capillary lumena with or without capsular adhesions as sufficient criterion for the diagnosis of segmental sclerosis (10). In contrast, the Columbia classification requires additional features such as intracapillary hyalinosis, foam cells, podocyte alterations and intracapillary cellularity to define the five different types of FSGS lesions (21,24). We also take this opportunity to emphasize the fact that it is possible to distinguish objectively and reproducibly between the S variable of Oxford classification and the FSGS of the Columbia classification. As discussed earlier, the lesions of podocyte hypertrophy/hyperplasia and intracapillary hyalinosis favor the later over former and these should be looked for carefully when examining renal biopsies from patients with IgAN with segmental glomerular sclerotic lesions. We additionally hypothesize that S variable of Oxford classification represents an early stage in the progression of glomerular lesions in IgAN and the FSGS lesion, the more advanced stage with injury to the podocyte compartment of the glomeruli, which finally culminates in the diffuse chronic sclerosing glomerulonephritis (GN) and end-stage renal disease (ESRD). We believe that the lesions of FSGS, as defined by Columbia classification, represent an advanced morphological stage of progression in IgAN and do not represent idiopathic FSGS superimposed on IgAN as two separate but concurrent diseases. In conclusion, the presence of FSGS-like lesions in the background of IgAN is associated with the poor clinical and pathological prognostic factors and outcome of this disease and the lesions are of prognostic significance. Two types of segmental sclerosing lesions can be identified on careful renal biopsy examination and an attempt should be made to subclassify them as these have vastly different prognosis.

Authors’ contributions

MM wrote the paper, drafted the paper and gave final approval. HN provided intellectual input and help in preparing the paper.

Conflict of interests

The author declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

Funding/Support

None.
  24 in total

1.  Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort.

Authors:  Shubha S Bellur; Stéphan Troyanov; H Terence Cook; Ian S D Roberts
Journal:  Nephrol Dial Transplant       Date:  2011-01-27       Impact factor: 5.992

2.  Focal segmental glomerulosclerosis in IgA nephropathy: a result of primary podocyte injury?

Authors:  H Terence Cook
Journal:  Kidney Int       Date:  2011-03       Impact factor: 10.612

3.  Oxford classification of IgA nephropathy: Broadening the scope of the classification.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2012-04-05

4.  Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.

Authors:  Khalil El Karoui; Gary S Hill; Alexandre Karras; Luc Moulonguet; Valérie Caudwell; Alexandre Loupy; Patrick Bruneval; Christian Jacquot; Dominique Nochy
Journal:  Kidney Int       Date:  2010-12-22       Impact factor: 10.612

5.  Predicting progression in IgA nephropathy.

Authors:  L P Bartosik; G Lajoie; L Sugar; D C Cattran
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

6.  The Oxford classification of IgA nephropathy: single centre experience.

Authors:  Ladislava Grcevska; Vesna Ristovska; Vladimir Nikolov; Gordana Petrusevska; Maja Milovanceva-Popovska; Momir Polenakovic
Journal:  Prilozi       Date:  2010

7.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

8.  Significance of immunohistochemical findings in Oxford classification of IgA nephropathy: The need for more validation studies.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2013-07-01

9.  Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy.

Authors:  Hamid Nasri; Shahram Sajjadieh; Saeed Mardani; Ali Momeni; Alireza Merikhi; Yahya Madihi; Alaleh Ghiessari; Afsoon Emami Naieni
Journal:  J Nephropathol       Date:  2013-07-01

10.  Validation of the Oxford classification of IgA nephropathy for pediatric patients from China.

Authors:  Weibo Le; Cai-Hong Zeng; Zhangsuo Liu; Dong Liu; Qing Yang; Rui-Xia Lin; Zheng-Kun Xia; Zhong-Min Fan; Guanghua Zhu; Ying Wu; Hong Xu; Yihui Zhai; Ying Ding; Xiaoqing Yang; Shaoshan Liang; Hao Chen; Feng Xu; Qian Huang; Hongbing Shen; Jianming Wang; Agnes B Fogo; Zhi-Hong Liu
Journal:  BMC Nephrol       Date:  2012-11-27       Impact factor: 2.388

View more
  3 in total

1.  IgM nephropathy: timely response to a call for action.

Authors:  Muhammed Mubarak; Hamid Nasri
Journal:  J Renal Inj Prev       Date:  2013-11-02

2.  Comment on: Association of Proteinuria with Various Clinical Findings and Morphologic Variables of Oxford Classification in Immunoglobulin A Nephropathy Patients.

Authors:  Mohammad-Reza Ardalan
Journal:  Int J Prev Med       Date:  2014-10

3.  Urinary C5b-9 as a Prognostic Marker in IgA Nephropathy.

Authors:  Byung Chul Yu; Jin Hoon Park; Kyung Ho Lee; Young Seung Oh; Soo Jeong Choi; Jin Kuk Kim; Moo Yong Park
Journal:  J Clin Med       Date:  2022-02-03       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.